NEOG 📈 Neogen - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6404911066
NEOG: Diagnostic Kits, Veterinary Products, Pharmaceuticals, Vaccines, Cleaning Supplies
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared food products and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. The company was incorporated in 1981 and is headquartered in Lansing, Michigan. Web URL: https://www.neogen.com
Additional Sources for NEOG Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NEOG Stock Overview
Market Cap in USD | 2,778m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 1989-08-23 |
NEOG Stock Ratings
Growth 5y | -77.3% |
Fundamental | -21.4% |
Dividend | - |
Rel. Strength Industry | -923 |
Analysts | 4/5 |
Fair Price Momentum | 9.82 USD |
Fair Price DCF | - |
NEOG Dividends
No Dividends PaidNEOG Growth Ratios
Growth Correlation 3m | -64% |
Growth Correlation 12m | -33.5% |
Growth Correlation 5y | -78.4% |
CAGR 5y | -17.43% |
CAGR/Mean DD 5y | -0.45 |
Sharpe Ratio 12m | -0.98 |
Alpha | -65.80 |
Beta | 0.95 |
Volatility | 50.76% |
Current Volume | 1254.4k |
Average Volume 20d | 2009.5k |
What is the price of NEOG stocks?
As of December 28, 2024, the stock is trading at USD 12.43 with a total of 1,254,373 shares traded.
Over the past week, the price has changed by +3.41%, over one month by -12.28%, over three months by -25.43% and over the past year by -39.51%.
As of December 28, 2024, the stock is trading at USD 12.43 with a total of 1,254,373 shares traded.
Over the past week, the price has changed by +3.41%, over one month by -12.28%, over three months by -25.43% and over the past year by -39.51%.
Is Neogen a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Neogen is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -21.38 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEOG as of December 2024 is 9.82. This means that NEOG is currently overvalued and has a potential downside of -21%.
Neither. Based on ValueRay Fundamental Analyses, Neogen is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -21.38 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEOG as of December 2024 is 9.82. This means that NEOG is currently overvalued and has a potential downside of -21%.
Is NEOG a buy, sell or hold?
Neogen has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy NEOG.
Neogen has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy NEOG.
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for NEOG stock price target?
According to ValueRays Forecast Model, NEOG Neogen will be worth about 10.8 in December 2025. The stock is currently trading at 12.43. This means that the stock has a potential downside of -13.52%.
According to ValueRays Forecast Model, NEOG Neogen will be worth about 10.8 in December 2025. The stock is currently trading at 12.43. This means that the stock has a potential downside of -13.52%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 16.5 | 32.7% |
Analysts Target Price | 22.3 | 79% |
ValueRay Target Price | 10.8 | -13.5% |